Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Legend Biotech (LEGN – Research Report) and Valeo Pharma (VPHIF – Research Report).
Legend Biotech (LEGN)
In a report released today, Sami Corwin from William Blair maintained a Hold rating on Legend Biotech. The company’s shares closed last Monday at $60.32.
According to TipRanks.com, Corwin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Legend Biotech has an analyst consensus of Strong Buy, with a price target consensus of $90.01.
See today’s best-performing stocks on TipRanks >>
Valeo Pharma (VPHIF)
Echelon Wealth Partners analyst Stefan Quenneville maintained a Buy rating on Valeo Pharma today and set a price target of C$0.80. The company’s shares closed last Friday at $0.14, close to its 52-week low of $0.10.
According to TipRanks.com, Quenneville is ranked #7514 out of 8631 analysts.
Valeo Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $0.58.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LEGN:
